ATRC - エイトリキュア （AtriCure Inc.） エイトリキュアATRCのチャート
ATRCの企業情報
| symbol | ATRC |
|---|---|
| 会社名 | AtriCure Inc （エイトリキュア） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Medical/Dental Instruments |
| 業種 | 医療機器_医療用品_ディストリビュ―タ― 医療関連（Health Care） |
| 概要 | 事業概要 アトリキュア（AtriCure Inc.）は心房細動（Afib）ソリューション会社である。同社は主に心臓組織の外科的アブレーション用に設計されたデバイスと、左心耳を除外するように設計されたシステムを開発、製造、販売している。これには、一定の開放的な手技を受けている患者の永続的かつ永続的な形態のAfibの治療用のIsolator Synergy Ablation Systemを含む、心臓組織の切除用の各種の製品ラインがある。それには、ラジオ周波数アブレーションデバイスおよびcryoICEクリオアブレーションシステム、および左心耳の除外用の製品ラインを含む、心臓組織アブレーションのための2つの主要な製品ラインがある。同社はまた、Lumitip解剖器具および再使用可能な心臓手術（弁）器具のEstechラインを販売している。そのcryoICE凍結手術製品ラインは多様な凍結切除装置を提供する。AtriClip左心房付属器排除システムは、心臓の左心耳（LAA）を閉塞するように設計されている。 エイトリキュアは、米国の医療機器メ―カ―。主な製品は、双極高周波電気メスシステム｢AtriCure RF｣、心房細動治療用チタン製クリップ｢AtriClip｣、電気手術システム｢Synergy｣など。北米、欧州、アジアで製品を販売する。本社は、オハイオ州ウエストチェスタ―。 AtriCure, Inc. provides innovative technologies for the treatment of Afib and related conditions. Afib affects more than 33 million people worldwide. Electrophysiologists and cardiothoracic surgeons around the globe use AtriCure technologies for the treatment of Afib and reduction of Afib related complications. AtriCure's Isolator ® Synergy™ Ablation System is the first and only medical device to receive FDA approval for the treatment of persistent Afib. AtriCure's AtriClip ® Left Atrial Appendage Exclusion System products are the most widely sold LAA management devices worldwide. |
| 本社所在地 | 7555 Innovation Way Mason OH 45040 USA |
| 代表者氏名 | Scott William Drake スコット・ウィリアム・ドレイク |
| 代表者役職名 | Independent Chairman of the Board |
| 電話番号 | +1 513-755-4100 |
| 設立年月日 | 36800 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2005年 |
| 従業員数 | 570人 |
| url | www.atricure.com |
| nasdaq_url | https://www.nasdaq.com/symbol/atrc |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -8.51300 |
| 終値（lastsale） | 32.53 |
| 時価総額（marketcap） | 1150317499.79 |
| 時価総額 | 時価総額（百万ドル） 1228.918 |
| 売上高 | 売上高（百万ドル） 187.00800 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 1244.33 |
| 当期純利益 | 当期純利益（百万ドル） -19.14100 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 AtriCure Inc. revenues increased 14% to $98.8M. Net loss decreased 39% to $10.5M. Revenues reflect United States segment increase of 15% to $79.3M Europe segment increase of 16% to $12.6M. Lower net loss reflects Research and development expenses - Bala decrease of 4% to $16.8M (expense) Interest Income increase of 95% to $199K (income). |
ATRCのテクニカル分析
ATRCのニュース
Radiofrequency Ablation Device Market - Boston Scientific, St Jude Medical, Medtronic, Covidien and Stryker, Imricor Medical Systems, AtriCure, BIOTRONIK, MicroPort Scientific and Spacelabs Healthcare. 2021/06/28 13:30:33 OpenPR
Coherent Market Insights has announced the addition of the Global Radiofrequency Ablation Device Market Size, Status and Forecast 2027, The report classifies the market in a precise manner to offer detailed insights about the aspects responsible for augmenting as well
AtriCure tops list of Cincinnati public companies that pay their employees the most 2021/06/18 08:14:04 Business Journals
AtriCure tops list of Cincinnati public companies that pay their employees the most - Cincinnati Business Courier Cincinnati Business Courier
Appointments and advancements for June 15, 2021 2021/06/15 16:00:00 BioWorld
New hires and promotions in the med-tech industry, including: Adapthealth, Atricure, Augmedix, Deepcell, Edap Tms, Endra, Helius Medical Technologies, One Drop, Ortho Regenerative Technologies, Quil, Stentit, Talkspace.
AtriCure Names Two New Members to the Board of Directors 2021/06/15 11:00:00 Business Wire
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that Deborah H. Telman and Maggie Yuen have been elected to its Board of Directors. Ms. Telman has spent over 20 years in senior executive roles at global companies. She is Executive Vice President and General Counsel for Organon (NYSE: OGN), a global healthcare company formed in June 2021 through a spinoff from
Cryotherapy Ablation Device Market Development, Market Trends, Key Driven Factors, Segmentation And Forecast To 2021-2027| Icecure Medical, AtriCure, Medtronic 2021/06/08 13:10:46 Jumbo News
Los Angeles, United State: The report is a compilation of comprehensive research studies on various aspects of the global Cryotherapy Ablation Device Market. With accurate data and highly authentic information, it makes a brilliant attempt to provide a real, transparent picture of current and future situations of the global Cryotherapy Ablation Device market. Market participants []
Cardiac Prosthetic Devices Market | Abbott Laboratories, Abiomed, Inc., AtriCure, Inc., Boston Scientific Corporation, Edward Lifesciences Corporation BIOTRONIK, Braile Biomedica, CryoLife, Inc., Labcor Laboratrios 2021/03/23 05:50:11 OpenPR
Cardiac Prosthetic Devices Market report is an in-depth analysis study offered which explains necessary aspects like competition, segmentation, and regional growth in excessive detail. As a part of competitive analysis, the analysis study includes thorough company identification of leading players
Radiofrequency Ablation Devices Market Overview, Top Players Analysis, Business Development Strategies and Sales Revenue 2027 | AngioDynamics, Inc., Hologic, Inc., AtriCure, Inc., and Johnson & Johnson 2021/03/17 13:06:22 OpenPR
A new report published by Allied Market Research titled, "Radiofrequency Ablation Devices Market was valued at $1,729 million in 2015, and is expected to reach $3,785 million by 2022, supported by a CAGR of 11.8% during the forecast period 2016-2027" Download
Atrial Fibrillation Market to reach US$ 18,085.96 million by 2027 and to grow at a CAGR of 14.0% - AtriCure, Biosense Webster, CardioFocus, Biotronik 2021/03/08 06:59:41 OpenPR
Atrial fibrillation also referred to as AFib or AF is a medical condition that causes irregular heartbeat (arrhythmia) and which can further lead to blood clots, stroke, heart failure and other heart-related complications. The global atrial fibrillation market is driven
AtriCure Announces Labeling Expansion for Cryo Nerve Block Therapy 2021/01/04 13:00:00 Business Wire
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance of additional labeling claims for cryo nerve block (cryoNB) therapy to include the treatment of adolescent patients (12-21 years of age). The cryoICE® and cryoSPHERE™ cryoablation probes are designed to temporarily block pain by ablati
AtriCure to Participate in Upcoming Piper Sandler 32nd Annual Virtual Healthcare Conference 2020/11/19 13:00:00 Business Wire
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that the company will participate in the upcoming Piper Sandler 32nd Annual Virtual Healthcare Conference. Conference Dates: Tuesday, December 1 to Thursday December 3, 2020 A link to the fireside chat presentation will be available on the “Investors” section of the Company’s website at https://ir.atric
Cardiac Prosthetic Devices Market | Abbott Laboratories, Abiomed, Inc., AtriCure, Inc., Boston Scientific Corporation, Edward Lifesciences Corporation BIOTRONIK, Braile Biomedica, CryoLife, Inc., Labcor Laboratrios 2021/03/23 05:50:11 OpenPR
Cardiac Prosthetic Devices Market report is an in-depth analysis study offered which explains necessary aspects like competition, segmentation, and regional growth in excessive detail. As a part of competitive analysis, the analysis study includes thorough company identification of leading players
Radiofrequency Ablation Devices Market Overview, Top Players Analysis, Business Development Strategies and Sales Revenue 2027 | AngioDynamics, Inc., Hologic, Inc., AtriCure, Inc., and Johnson & Johnson 2021/03/17 13:06:22 OpenPR
A new report published by Allied Market Research titled, "Radiofrequency Ablation Devices Market was valued at $1,729 million in 2015, and is expected to reach $3,785 million by 2022, supported by a CAGR of 11.8% during the forecast period 2016-2027" Download
Atrial Fibrillation Market to reach US$ 18,085.96 million by 2027 and to grow at a CAGR of 14.0% - AtriCure, Biosense Webster, CardioFocus, Biotronik 2021/03/08 06:59:41 OpenPR
Atrial fibrillation also referred to as AFib or AF is a medical condition that causes irregular heartbeat (arrhythmia) and which can further lead to blood clots, stroke, heart failure and other heart-related complications. The global atrial fibrillation market is driven
AtriCure Announces Labeling Expansion for Cryo Nerve Block Therapy 2021/01/04 13:00:00 Business Wire
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance of additional labeling claims for cryo nerve block (cryoNB) therapy to include the treatment of adolescent patients (12-21 years of age). The cryoICE® and cryoSPHERE™ cryoablation probes are designed to temporarily block pain by ablati
AtriCure to Participate in Upcoming Piper Sandler 32nd Annual Virtual Healthcare Conference 2020/11/19 13:00:00 Business Wire
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that the company will participate in the upcoming Piper Sandler 32nd Annual Virtual Healthcare Conference. Conference Dates: Tuesday, December 1 to Thursday December 3, 2020 A link to the fireside chat presentation will be available on the “Investors” section of the Company’s website at https://ir.atric